首页> 外文期刊>OncoTargets and therapy >Biological and Clinical Significance of GATA3 Detected from TCGA Database and FFPE Sample in Bladder Cancer Patients
【24h】

Biological and Clinical Significance of GATA3 Detected from TCGA Database and FFPE Sample in Bladder Cancer Patients

机译:从膀胱癌患者中检测到TCGA数据库和FFPE样品的GATA3的生物学和临床意义

获取原文
       

摘要

Purpose: The purpose of the present study was to investigate the biological and clinical significance of GATA binding protein 3 (GATA3) in bladder cancer patients. Patients and Methods: For the detection of the correlation between GATA3 expression and bladder cancer, we downloaded the mRNA expression data from the Cancer Genome Atlas (TCGA) database and conducted immunohistochemistry staining on formalin-fixed paraffin-embedded (FFPE) sample tissues. Then, bladder cancer cell lines were utilized to investigate the potential functions of GATA3 by cell apoptosis, proliferation and cycle assays. Results: The mRNA data from TCGA database and bladder cancer cell lines suggested that GATA3 mRNA expression was significantly higher compared with normal tissues and cells. Conversely, the Western blot assay revealed that the expression of GATA3 was significantly lower in bladder cancer than normal urothelial cell line. Additionally, we found that over-expression of GATA3 was significantly associated with tumor subtype ( P = 0.001 in TCGA; P = 0.004 in FFPE tissues), earlier clinical stage ( P 0.001 in TCGA; P 0.001 in FFPE) and lower grade tumor ( P = 0.057 in TCGA; P = 0.002 in FFPE). Kaplan-Meier analysis and multivariate Cox regression analysis indicated that age ( P 0.001 in both cohort), clinical stage ( P = 0.028 in TCGA; P = 0.011 in FFPE), recurrence ( P 0.001) and low GATA3 in TCGA cohort ( P = 0.035) but high GATA3 in FFPE cohort ( P = 0.033) were independent risk factors for overall survival in patients. The assay to detect potential functions of GATA3 indicated that this biomarker could arrest the cell cycle of G2/M and S phase in T24 cells, and inhibit bladder cancer cells proliferation. Conclusion: Collectively, our findings identified that GATA3 served as an important prognosis biomarker for bladder cancer patients. However, the mechanism of GATA3 in bladder cancer deserves further studies.
机译:目的:本研究的目的是探讨Gata结合蛋白3(GATA3)在膀胱癌患者中的生物学和临床意义。患者和方法:为了检测GATA3表达和膀胱癌之间的相关性,我们从癌症基因组ATLAS(TCGA)数据库中下载了MRNA表达数据,并在福尔马林固定的石蜡包埋(FFPE)样品组织上进行免疫组化染色。然后,利用膀胱癌细胞系来研究GATA3通过细胞凋亡,增殖和循环测定的潜在功能。结果:来自TCGA数据库和膀胱癌细胞系的mRNA数据表明,与正常组织和细胞相比,GATA3 mRNA表达明显高得多。相反,Western印迹测定显示,膀胱癌的GATA3表达明显低于正常的尿路上皮细胞系。另外,我们发现GATA3的过表达与肿瘤亚型显着相关(在TCGA中P = 0.001; P = 0.004在FFPE组织中),早期的临床阶段(P <0.001在TCGA中; FFPE中的P <0.001)和较低的级别肿瘤(P = 0.057在TCGA中; P = 0.002在FFPE中)。 Kaplan-Meier分析和多元COX回归分析表明,年龄(群组中的P <0.001),临床阶段(在TCGA中的P = 0.028; P = 0.011在FFPE中),TCGA队列中的复发(P <0.001)和低GATA3( P = 0.035)但FFPE队列中的高GATA3(P = 0.033)是患者整体生存的独立危险因素。检测GATA3潜在功能的测定表明,该生物标志物可以在T24细胞中抑制G2 / m和S相的细胞周期,并抑制膀胱癌细胞增殖。结论:集体,我们的研究结果确定了GATA3作为膀胱癌患者的重要预后生物标志物。然而,GATA3在膀胱癌中的机制值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号